Day 1 :
Ukrainian Anti-Cancer Institute, Austria
Time : 10:00 - 10:40
Dr. Wassil Nowicky — Dipl. Ing., Dr. techn., DDDr. h. c., Director of “Nowicky Pharma” and President of the Ukrainian Anti-Cancer Institute (Vienna, Austria). He has finished his study at the Radiotechnical Faculty of the Technical University of Lviv (Ukraine) at the end of 1955 with graduation to “Diplomingeniueur” in 1960 which title was nostrificated in Austria in 1975. Inventor of the anticancer preparation on basis of celandine alkaloids “NSC-631570”. Author of over 300 scientific articles dedicated to cancer research. Dr. Wassil Nowicky is a real member of the New York Academy of Sciences, member of the European Union for applied immunology and of the American Association for scientific progress, honorary doctor of the Janka Kupala University in Hrodno, doctor “honoris causa” of the open international university on complex medicine in Colombo, honorary member of the Austrian Society of a name of Albert Schweizer. He has received the award for merits of National guild of pharmacists of Americ, the award of Austrian Society of sanitary, hygiene and public health services and others.
The first publication on the using NSC‐631570 in malignant melanoma describes the full remission in a patient with metastases to the lung. A long lasting remission (more than 10 years without recurrence) has been observed in a patient with malignant nodular melanoma after the treatment with NSC‐631570. At the beginning of the NSC‐631570 therapy liver metastases were present and melanin was excreted with urine. The effects of NSC‐631570 alone and in combination with the pathogen associated molecules (PAM) on the cell cycle and apoptotic induction were compared in two melanoma cell lines MM‐4 and MM‐4M2 with different metastatic properties (cell division rate, hematogenous metastazing, sensitivity to the TNF‐induced apoptosis). Apoptosis induction and cell viability were analyzed using trypan blue exclusion test, morphological criteria, DNA gel electrophoresis, and flow cytometry. Cell cycle distribution of tumor cells was estimated by flow cytometry. The therapy with NSC‐631570 induced apoptosis in both melanoma cell lines in a dose‐dependant matter. The cell line with higher metastatic potential was more sensitive to NSC‐631570. In the cell line with low metastatic potential, combined use of NSC‐631570 and PAM induced apoptosis more effectively.
National Center for Cancer Care and Research, Qatar
Time : 10:40-11:20
Kakil Ibrahim Rasul is working at National Center for Cancer Care and Research, Qatar
Hepatocellular carcinoma (HCC) is 6th common cancer in incidence and 3rd leading cause of death worldwide, Increasing incident in developing countries including the gulf coutries; it is hepatitis associated cirrhosis leading to HCC in our area. Growing problem of NASH related Liver cirrhosis also is also rising in the Gulf region. HCC has a unique geographic distribution that is likely to be determined by specific etiologic factors. There is a distinctive difference in sex and age related occurrence of disease. In the Gulf region, there are contradicting data on the prevalence and death rates due to HCC. In this review we highlight some aspects of HCC specific to the Gulf region. A retrospective analysis of 150 patient’s data is presented, including demographic, epidemiological, aetiological disease status assessment with child Pugh criteria, modes of treatment and treatment related outcome. Hepatitis C virus (HCV) infection was the most common (45%) documented etiology, similar to Western European countries, followed by hepatitis B virus (HBV) infection in 27% of cases, alcoholic liver disease only in six patients (4%). Child-Pugh assessment was A in 33%, B in 37% and C in 30% of observed patients. Surgery (liver resection or transplantation) was performed in 12% and local ablation in 5% of cases. The others were treated by chemo-embolization in 17% and by systemic therapy with sorafenib in 13% of patients. Nearly half of the patients (53%) were in advanced stages and received palliative treatment.
In other part of the presentation, have started regular Multidisciplinary (MDT) meeting at our center (NCCCR) we good collaboration with intervention radiologist we have good improvement in our patient treatment outcome. Included some examples of case presentation
To improve the outcome of treatment in HCC patients in the Gulf region, an effective and strategic screening program must be implemented for early diagnosis and clear multidisciplinary group working for the treatment to improve the outcome of this mostly fatal disease.
Soonchunhyang University Hospital, Korea
Time : 11:20-12:00
Jae Pil Hwang is working in Nuclear Medicine department at Soon Chun Hyang University Bucheon Hospital and Soon Chun Hyang Medical School, Repubilc of Korea, where he researches, teaches, interpretate of medical imaging and treat cancer patients both in hospital and education institutions. He graduated from the Gyeongsan National University of Korea, with bachelors and master degrees in medicine in 2003 and 2011. Before assistant professor, he worked at Soon Chun Hyang University Hospital as fellow and clinical assistant professor of Nuclear Medicine and Radiology. His another position is head of Department of Nuclear Medicine, an editor of Radiology and Medical webzine, an editor of Clinical Radiology and Case Reports, full membership of Korean Society of Nuclear Medicine (KSNM) and sub-director of public relations of KSNM.
In recent decades, 18F–fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) is non-invasive imaging modality and has been routinely used for diagnosis, staging, restaging, assessing treatment response, detecting recurrence after treatment and evaluating prognosis of patients in various malignancies.
Because tumor FDG uptake is associated with tumor aggressiveness, positive tumor FDG uptake on visual analysis and intensity of uptake, expressed as maximum standardized uptake value (SUVmax), volumetric parameters including metabolic tumor volume (MTV), total lesion glycolysis (TLG) and intratumoral heterogeneity reflecting the biological tumor conditions such as metabolism, hypoxia, necrosis, and cellular proliferation.
In this forum, we overview the introduction and clinical applications of oncologic PET/CT that investigated metabolic characteristics on various cancers, and we discuss the clinical roles of PET/CT for patients with malignant disease and for clinical oncologists. Although FDG continues to be the most widely used radiotracer for PET imaging, some of the another or newer PET imaging agents that have been studied in humans will also be announced